Antigen Presentation in Human Autoimmune Diseases
人类自身免疫性疾病中的抗原呈递
基本信息
- 批准号:7186646
- 负责人:
- 金额:$ 82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-09-30 至 2008-09-14
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntigen PresentationAntigen-Presenting CellsAntigensAreaAutoimmune DiseasesB-LymphocytesBiochemistryCerebrospinal FluidClassClinicalDiseaseDissectionFunctional disorderGenerationsGreen Fluorescent ProteinsHumanInflammatoryKnock-in MouseLasersLifeLightMHC Class II GenesMicroscopyMultiple SclerosisNeuraxisOptic NervePathogenicityPatientsPeptide LibraryPhotonsPopulationProcessProteinsProteomicsRecombinant AntibodyResearch PersonnelSourceSpecificityT-Cell Immunologic SpecificityT-Cell ReceptorT-LymphocyteTechnologyTissuesbasecombinatorialinnovationmouse modelnew technologynovel strategiesprogramstool
项目摘要
DESCRIPTION (provided by applicant): This program project will continue to focus on antigen presentation and T cell recognition in patients with multiple sclerosis. During the past three years considerable efforts were directed at establishing and validating new technology, now in place for the continuation of the PPG. These novel approaches will be used to visualize antigen presentation in the central nervous system and to molecularly define the T cell and B cell populations involved in the disease process. Project 1 has developed a novel approach for the generation of MAC class II terriers, which will be used to quantify and characterize antigen-specific COD T cells in MS patients and a humanized mouse model of the disease. Project 2 has isolated expanded populations of T cells from the cerebrospinal fluid of patients with MS and will characterize the antigen receptors of T cell and B cell populations. Combinatorial peptide libraries and MHC class II terriers will be used to define the antigen specificity of T cell clones established from the cerebrospinal fluid. B cells will be isolated from cerebrospinal fluid by FACES and MS plaque tissue by laser capture micro dissection, so that recombinant antibodies can be expressed based on the isolated heavy and light chain sequences. Such recombinant antibodies provide an abundant source of these proteins for definition of their target specificity, to be established by a polemics approach, and assessment of pathogenicity. Project 3 will examine the entry of antigen presenting cells into the CNS using a newly created mouse model in which a GFP moiety is attached to the MHC class II beta chain through knock-in technology. The interaction of these GFP expressing antigen presenting cells with infiltrating T cells will be investigated in the optic nerve of live animals by 2-photon microscopy. Each of the investigators contributes a unique area of expertise and innovative approaches to this important clinical problem. The resulting program is highly synergistic and will allow the application of powerful new tools in proteomics and biochemistry to the pathophysiology of human inflammatory disease.
描述(申请人提供):该计划项目将继续关注多发性硬化症患者的抗原呈递和T细胞识别。在过去三年中,在建立和验证新技术方面作出了相当大的努力,这些新技术现已到位,以便继续实施私营部门保护计划。这些新的方法将被用来可视化中枢神经系统中的抗原呈递,并从分子上确定参与疾病过程的T细胞和B细胞群体。项目1已经开发了一种新的方法来产生MAC II类梗,该方法将用于量化和表征MS患者的抗原特异性CODT细胞和人源化的疾病小鼠模型。项目2已经从多发性硬化症患者的脑脊液中分离出扩增的T细胞群体,并将表征T细胞和B细胞群体的抗原受体。组合多肽文库和MHC II类载体将用于确定从脑脊液中建立的T细胞克隆的抗原特异性。通过激光捕获显微切割技术从脑脊液中分离出B细胞,并用激光捕获显微切割技术从MS斑块组织中分离出B细胞,从而根据分离的重链和轻链序列表达重组抗体。这种重组抗体提供了丰富的这些蛋白质的来源,用于确定它们的靶标特异性,将通过争论的方法建立,并评估致病性。项目3将使用一种新创建的小鼠模型来研究抗原提呈细胞进入中枢神经系统的情况,在该模型中,GFP部分通过敲入技术连接到MHC II类Beta链上。这些表达GFP的抗原提呈细胞与浸润性T细胞的相互作用将通过双光子显微镜在活体动物的视神经中进行研究。每个研究人员都为这一重要的临床问题贡献了独特的专业知识和创新的方法。由此产生的计划是高度协同的,并将允许将蛋白质组学和生物化学中的强大新工具应用于人类炎症性疾病的病理生理学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kai W Wucherpfennig其他文献
Cracking the code of human T-cell immunity
破解人类 T 细胞免疫的密码
- DOI:
10.1038/nbt.2626 - 发表时间:
2013-07-09 - 期刊:
- 影响因子:41.700
- 作者:
Christopher J Harvey;Kai W Wucherpfennig - 通讯作者:
Kai W Wucherpfennig
4-1bb Enrichment Enhances Adoptive T Cell Therapy for Hematological Malignancies Using a Novel Approach for Ex Vivo Immune Cell Priming with DC/Tumor Fusion Vaccine
- DOI:
10.1182/blood-2023-182381 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Kathrine S Rallis;Jessica Liegel;Giulia Cheloni;Poorva Bindal;Isabella Saldarriaga;Junyan Zhang;Georges Chedid;Joseph Abirached;John G. Clohessy;Sophia Adamia;Kai W Wucherpfennig;Donald Kufe;Jacalyn Rosenblatt;David Avigan - 通讯作者:
David Avigan
Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
- DOI:
10.1182/blood-2024-200876 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Prateek Pophali;Giulia Cheloni;Richard M. Stone;Kai W Wucherpfennig;Aric C. Hall;Amir T. Fathi;Lina Bisharat;Emma K Logan;Yiwen Liu;Donna S. Neuberg;Malgorzata McMasters;Jessica Liegel;Jacqueline S. Garcia;Daniel J. DeAngelo;Michele Narcis;Dina Stroopinsky;Pavania Elavalakanar;Ioannis S Vlachos;Ilene A. Galinsky;Jason Pyrdol - 通讯作者:
Jason Pyrdol
Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine
- DOI:
10.1182/blood-2024-208563 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Kathrine S Rallis;Jessica Liegel;Giulia Cheloni;Poorva Bindal;Isabella Saldarriaga;Junyan Zhang;Georges Chedid;Joseph Abirached;Jonah Lee;John G. Clohessy;Samprity Ankita;Rajeev Relangi;Lina Bisharat;Hazal Toros;Sophia Adamia;Jasper B Lee;Donald Kufe;Kai W Wucherpfennig;Jacalyn Rosenblatt;David Avigan - 通讯作者:
David Avigan
Kai W Wucherpfennig的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kai W Wucherpfennig', 18)}}的其他基金
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
MICA 免疫逃避的治疗靶向 - NKG2D 通路
- 批准号:
10380449 - 财政年份:2021
- 资助金额:
$ 82万 - 项目类别:
Core 1: Tumor Processing and Single Cell RNA sequencing Core
核心1:肿瘤处理和单细胞RNA测序核心
- 批准号:
10210225 - 财政年份:2020
- 资助金额:
$ 82万 - 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
- 批准号:
10029035 - 财政年份:2020
- 资助金额:
$ 82万 - 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
- 批准号:
10210221 - 财政年份:2020
- 资助金额:
$ 82万 - 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
- 批准号:
10224146 - 财政年份:2020
- 资助金额:
$ 82万 - 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
- 批准号:
10400167 - 财政年份:2020
- 资助金额:
$ 82万 - 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
- 批准号:
10477984 - 财政年份:2020
- 资助金额:
$ 82万 - 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
- 批准号:
10668947 - 财政年份:2020
- 资助金额:
$ 82万 - 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
- 批准号:
10684029 - 财政年份:2020
- 资助金额:
$ 82万 - 项目类别:
Core 1: Tumor Processing and Single Cell RNA sequencing Core
核心1:肿瘤处理和单细胞RNA测序核心
- 批准号:
10684050 - 财政年份:2020
- 资助金额:
$ 82万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 82万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 82万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 82万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 82万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 82万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 82万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 82万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 82万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 82万 - 项目类别: